BERKELEY, Calif.--Neomorphic Software has closed a deal with SyStemix, a Novartis company. Neomorphic's hidden-Markov-model-based technology will be used to find novel genes in SyStemix's proprietary sequences that are unable to be classified using existing sequence analysis tools. Martin Reese, Neomorphic's chief scientific officer, said the deal would give Neomorphic "the opportunity to work closely with geneticists to verify and optimize this technology towards the discovery of new genes."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.